Rezdiffra (Resmetirom) Standard Titration Schedule

What Is the Standard Resmetirom Titration Schedule?

Resmetirom titration follows a simple two-step protocol: 60 mg once daily for the first four weeks, followed by escalation to 100 mg once daily from week five onward. This approach was used in the key MAESTRO-NASH trial, where most participants reached the 100 mg maintenance dose. For women with body weight below 100 kg who experience tolerability issues, 80 mg once daily is an alternative target dose per the FDA-approved prescribing information.

The four-week lead-in at 60 mg is not a therapeutic dose plateau. It is a tolerability ramp. The drug's thyroid hormone receptor beta (THR-beta) selectivity means systemic thyroid effects are limited, but GI side effects, particularly nausea and diarrhea, are most common in the first few weeks and tend to subside at the maintenance dose.

The Two Dose Targets: 80 mg vs. 100 mg

The FDA prescribing label defines two maintenance doses:

• 100 mg once daily: recommended for all eligible patients after the four-week titration period
• 80 mg once daily: an option for patients weighing less than 100 kg who do not tolerate the 100 mg dose

Patients weighing 100 kg or more should target 100 mg regardless of tolerability concerns, because the 80 mg dose has not been shown to provide equivalent efficacy in that weight range. In MAESTRO-NASH, histologic response at 52 weeks was 26% for 100 mg vs. 14% for 80 mg vs. 10% for placebo, a difference that matters when you are deciding whether to push through early GI side effects.

Timing and Administration

Take resmetirom once daily at approximately the same time each day. The FDA label states it can be taken with or without food, though food may reduce nausea in the first weeks of titration. Do not crush or split the tablets.

If you miss a dose, take it as soon as you remember on the same day. Skip it if the next scheduled dose is within 12 hours. Do not double up.

Why the Titration Step Exists: Tolerability Data from MAESTRO-NASH

The four-week lead-in dose was selected based on pharmacokinetic modeling and the early safety data from MAESTRO-NASH phase 2. GI adverse events peaked in weeks one through six and were the most common reason for dose interruption.

In the MAESTRO-NASH phase 3 trial, nausea occurred in 30% of participants on 100 mg vs. 16% on placebo, and diarrhea in 32% vs. 18%. Most events were mild-to-moderate and resolved without discontinuation. Fewer than 6% of participants in the 100 mg arm discontinued due to adverse events, a figure that is worth keeping in mind when GI symptoms tempt you to stop early.

What to Do If Side Effects Arise During Titration

If nausea or diarrhea is significant at 60 mg, extend the lead-in period by one to two weeks before escalating. This is off-label practice, but clinically reasonable and consistent with general GI-tolerability management principles used for GLP-1 receptor agonists.

Dose interruptions of up to 14 days are acceptable without restarting the full titration sequence, per clinical practice consensus, though the FDA label does not specify a formal re-titration requirement after brief interruptions. If the break exceeds two weeks, restarting at 60 mg for four weeks is the conservative approach.

Hepatic Adverse Events and the LFT Threshold

Resmetirom is a liver-targeted drug, and ALT elevations above three times the upper limit of normal occurred in approximately 7% of MAESTRO-NASH participants on 100 mg vs. 4% on placebo at week 52, as reported in the NEJM primary publication. If ALT rises above five times the upper limit of normal, the FDA label recommends withholding resmetirom and investigating. Do not simply push through a significant LFT elevation during titration.

How Resmetirom Titration Differs Across Women's Life Stages

No published sub-group analysis has reported resmetirom titration outcomes stratified by menopausal status or menstrual cycle phase. This is an evidence gap. What follows reflects known sex-specific pharmacology, hormone-liver interactions, and extrapolation from the MAESTRO-NASH dataset, where women represented approximately 54% of enrolled participants at the 100 mg dose arm per the NEJM supplementary appendix.

Reproductive Years (Ages 18-40)

Women in their reproductive years are the least likely to have advanced MASH fibrosis, but PCOS changes that calculus. PCOS affects 8-13% of women of reproductive age and carries a substantially elevated risk of nonalcoholic fatty liver disease, with prevalence estimates of 30-70% in women with PCOS depending on the diagnostic criteria used. If you have PCOS-associated MASH with F2 or F3 fibrosis confirmed on biopsy or noninvasive testing, you are within the approved indication.

Titration in this group proceeds identically: 60 mg for four weeks, then 100 mg. There are no data suggesting the menstrual cycle alters resmetirom pharmacokinetics meaningfully, though THR-beta agonism could theoretically interact with estrogen-driven thyroid-binding globulin changes. Free T4 and TSH should be checked at baseline and at the three-month mark.

Contraception is non-negotiable in this life stage. See the pregnancy and lactation section below.

Trying to Conceive or Planning Pregnancy

Resmetirom is contraindicated in pregnancy. If you are actively trying to conceive, resmetirom should be discontinued before stopping contraception. There is no established washout window in the FDA label, and the drug's half-life is approximately 10 hours, suggesting it clears within a few days. A conservative two to four week washout before attempting conception is a reasonable clinical practice, though direct evidence is absent.

Perimenopause (Typically Ages 45-55)

Perimenopause is the life stage where MASH risk accelerates fastest in women. Declining estrogen reduces hepatic insulin sensitivity, drives visceral fat redistribution, and increases hepatic triglyceride accumulation. Women who had healthy liver function in their thirties can develop MASH with meaningful fibrosis within five to seven years of menopause onset.

If you are starting resmetirom during perimenopause, GI tolerability during titration may be complicated by vasomotor symptoms (nausea from hot flashes can overlap with drug-induced nausea). Tracking symptoms with a simple daily log during the first eight weeks helps distinguish drug side effects from vasomotor overlay.

Perimenopausal women on menopausal hormone therapy (MHT) should know that estrogen therapy, particularly oral formulations, can itself alter liver lipid metabolism. There are no interaction data between oral estradiol and resmetirom, but transdermal estradiol avoids first-pass hepatic metabolism and is a reasonable preference in women on resmetirom, consistent with general liver-health guidance from The Menopause Society.

Post-Menopause

Post-menopausal women with MASH are the group with the highest fibrosis stage at diagnosis and the highest urgency for treatment. The 100 mg target dose applies equally here. No dose reduction is required based on menopausal status alone.

Hepatic clearance may be modestly reduced in older post-menopausal women with age-related decline in CYP3A4 activity, though resmetirom is primarily metabolized by CYP2C8 and CYP3A4. The FDA label does not recommend dose adjustment based on age alone, but LFT monitoring every three months in the first year is especially important in this group.

Pregnancy, Lactation, and Contraception

Resmetirom is contraindicated in pregnancy. This is not a relative contraindication. Animal studies showed fetal harm at doses producing exposures overlapping with the human therapeutic range, as summarized in the FDA prescribing information. There are no adequate human pregnancy data. The drug is assigned a formal contraindication rather than a pregnancy category letter under the current FDA labeling framework.

What You Must Do Before Starting Resmetirom

1. Confirm a negative pregnancy test within seven days before the first dose.
2. Use effective contraception throughout treatment. The FDA label specifies contraception for women of reproductive potential for the duration of therapy.
3. If you become pregnant while on resmetirom, stop the drug immediately and contact your prescriber.

Lactation

There are no data on resmetirom transfer into human breast milk, its effect on milk production, or its effects on a breastfed infant. Because of the potential for harm, the FDA label advises against breastfeeding during resmetirom treatment. If MASH treatment is urgent in a post-partum woman, the decision to use resmetirom requires discontinuing breastfeeding.

Contraception Requirements in Detail

Any reliable contraception method is acceptable: combined oral contraceptives, progestin-only pills, IUD (hormonal or copper), implant, or barrier methods used consistently. There are no published drug-drug interactions between resmetirom and hormonal contraceptives, but women on enzyme-inducing medications (rifampin, certain antiepileptics) that reduce contraceptive efficacy should use a non-hormonal method or IUD.

Who Is the Right Candidate for Resmetirom and Who Is Not

Who This Is Right For

• Women with biopsy-confirmed or noninvasive-test-confirmed noncirrhotic MASH with F2 or F3 fibrosis
• Women with PCOS and MASH meeting fibrosis stage criteria
• Post-menopausal women with advancing MASH who have not responded to lifestyle modification
• Perimenopausal women with rapid fibrosis progression documented over 12-24 months
• Women with type 2 diabetes and MASH who are already on a GLP-1 receptor agonist (resmetirom and GLP-1 agonists can be used together; no formal interaction concern exists in the FDA label)

Who This Is Not Right For

• Pregnant women or women planning to conceive in the near term without a washout period
• Women with cirrhosis (Child-Pugh A, B, or C): resmetirom is not approved for cirrhotic MASH
• Women with decompensated liver disease of any cause
• Women breastfeeding who are unwilling to stop
• Women with known hypersensitivity to resmetirom or tablet components
• Women on strong CYP2C8 inhibitors (gemfibrozil) or inducers (rifampin) until a drug interaction review is completed, as these can substantially alter resmetirom exposure per the FDA label

Monitoring During and After Titration

Resmetirom requires structured follow-up, especially in the first 24 weeks. A reasonable monitoring framework based on the MAESTRO-NASH trial protocol and the FDA label is:

| Timepoint | Tests | |---|---| | Baseline (before first dose) | LFTs, lipids, TSH, free T4, pregnancy test, HbA1c if diabetic | | Week 4 (titration visit) | LFTs, tolerability review, dose escalation decision | | Week 12 | LFTs, lipids, TSH | | Week 24 | LFTs, lipids, TSH, noninvasive liver stiffness (FibroScan or MRE if available) | | Week 52 | Full metabolic panel, repeat noninvasive fibrosis assessment |

Lipid Changes to Expect

Resmetirom lowers LDL cholesterol. In MAESTRO-NASH, the 100 mg dose reduced LDL by a mean of approximately 16% from baseline at 52 weeks. If you are already on a statin, your LDL may drop further. Statin dose adjustment is not automatically required but worth reviewing at the week 12 visit.

Triglycerides also fell: the 100 mg arm showed a median reduction of approximately 26% in triglycerides at week 52, which is meaningful for women with PCOS-associated hypertriglyceridemia.

Thyroid Function

Because resmetirom targets THR-beta selectively, systemic thyroid effects are limited, but not zero. TSH remained within the normal range for most MAESTRO-NASH participants. Women with pre-existing hypothyroidism on levothyroxine should have TSH rechecked at weeks 4 and 12, since THR-beta agonism could alter levothyroxine requirements. A 2024 analysis found no significant between-group differences in TSH at 52 weeks, but the trial excluded women with untreated thyroid disease.

Drug Interactions Relevant to Women

Several interactions deserve specific attention in a female patient population:

Oral hormonal contraceptives: No formal interaction study exists. The FDA label does not flag a specific concern, but resmetirom is a substrate and mild inhibitor of some hepatic transporters. Monitor for any unexpected breakthrough bleeding, which could signal altered contraceptive hormone exposure.

Statins: Resmetirom inhibits OATP1B1 and OATP1B3 transporters. This can increase statin plasma concentrations. The FDA label recommends avoiding the highest doses of rosuvastatin (40 mg) and pravastatin (40 mg) with resmetirom, and capping simvastatin at 20 mg.

GLP-1 receptor agonists: No pharmacokinetic interaction is expected. Women on semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound) may use resmetirom concurrently. Both drug classes reduce hepatic fat by different mechanisms, and combination use is an active area of research.

Gemfibrozil: A strong CYP2C8 inhibitor. Co-administration increases resmetirom exposure approximately 2.5-fold per the FDA label and is contraindicated.

The Evidence Gap: What We Do Not Know About Resmetirom in Women

Women made up the majority of MAESTRO-NASH participants at the 100 mg arm, but the trial results were not published with sex-stratified primary endpoints. We do not know whether:

• Women achieve equivalent histologic response rates to men at 100 mg
• The four-week titration window is optimal for perimenopausal women with altered hepatic blood flow
• Resmetirom interacts with endogenous estrogen fluctuations during the menstrual cycle in a clinically meaningful way
• Post-menopausal women on MHT show different lipid or fibrosis responses

This is not unique to resmetirom. As noted in the NIH Office of Research on Women's Health, women remain underrepresented in liver disease pharmacology trials despite carrying a disproportionate burden of autoimmune hepatitis and a rapidly growing MASH burden after menopause. The titration schedule you follow today is derived from trial data that was not designed to answer women-specific questions. That gap should inform shared decision-making, not prevent treatment, but it deserves honesty.

A Practical Week-by-Week Titration Guide for Women

Here is a concrete calendar to share with your prescriber or keep in your own records:

Days 1-28 (Weeks 1-4): 60 mg once daily

• Take each morning with or without food, same time daily
• Log nausea, diarrhea, and any unusual fatigue each evening (a simple 1-10 scale works)
• Return-to-clinic or telehealth check-in at the end of week 4 for LFT review and dose escalation confirmation
• Confirm contraception method is active and reliable

Day 29 onward (Week 5+): 100 mg once daily

• If weight is below 100 kg and GI symptoms at 60 mg were moderate-to-severe, discuss 80 mg as the maintenance target with your clinician before auto-escalating
• Expect GI symptoms to peak in weeks 5-7 and then decline
• Repeat LFTs at week 12

Week 24: First efficacy checkpoint

• Noninvasive fibrosis assessment (FibroScan or MRI-PDFF) gives a preliminary liver fat signal
• In MAESTRO-NASH, MRI-PDFF liver fat fraction fell by a mean of 10.4 percentage points from baseline at 52 weeks on 100 mg, with early directional changes visible by week 24 in the trial

Do not expect a biopsy-confirmed response before 52 weeks. Resmetirom works slowly. Four weeks at 60 mg is a ramp, not the drug working at full capacity.